Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers

Nouredin Messaoudi; Aude Vanlander; Andrew A Gumbs

doi:10.1038/s41416-024-02808-2

Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers

Br J Cancer. 2024 Sep;131(4):617-618. doi: 10.1038/s41416-024-02808-2. Epub 2024 Jul 31.

Authors

Nouredin Messaoudi¹, Aude Vanlander¹, Andrew A Gumbs^{2

3}

Affiliations

¹ Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) and Europe Hospitals, Brussels, Belgium.
² Department of General-, Visceral-, Vascular- and Transplantation Surgery, University of Magdeburg, Magdeburg, Germany. [email protected].
³ Department of Advanced & Minimally Invasive Surgery, American Hospital of Tbilisi, Tbilisi, Republic of Georgia. [email protected].

PMID: 39085361
PMCID: PMC11333485 (available on 2025-07-31)
DOI: 10.1038/s41416-024-02808-2

Abstract

Non-pancreatic periampullary tumors have long been neglected, leading to blurred adjuvant treatment strategies. Recent research, like the ISGACA group's study, is uncovering nuances in chemotherapy efficacy for these diverse cancers. Tailored approaches show promise, with artificial intelligence (AI) aiding in personalized treatment plans.

Publication types

Editorial

MeSH terms

Ampulla of Vater / pathology
Artificial Intelligence*
Chemotherapy, Adjuvant / methods
Common Bile Duct Neoplasms / drug therapy
Common Bile Duct Neoplasms / pathology
Humans